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Essentials
• Factor XIIIa inhibits fibrinolysis by forming fibrin-
fibrin and fibrin-inhibitor cross-links.
• Conflicting studies about magnitude and mechanisms of
inhibition have been reported.
• Factor XIIIa most strongly inhibits lysis of mechani-
cally compacted or retracted plasma clots.
• Cross-links of a2-antiplasmin to fibrin prevent the inhi-
bitor from being expelled from the clot.
Summary. Background: Although insights into the under-
lying mechanisms of the effect of factor XIII on fibrinoly-
sis have improved considerably in the last few decades, in
particular with the discovery that activated FXIII
(FXIIIa) cross-links a2-antiplasmin to fibrin, the topic
remains a matter of debate. Objective: To elucidate the
mechanisms of the antifibrinolytic effect of FXIII. Meth-
ods and Results: Platelet-poor plasma clot lysis, induced
by the addition of tissue-type plasminogen activator, was
measured in the presence or absence of a specific FXIIIa
inhibitor. Both in a turbidity assay and in a fluorescence
assay, the FXIIIa inhibitor had only a small inhibitory
effect: 1.6-fold less tissue-type plasminogen activator was
required for 50% clot lysis in the presence of the FXIIIa
inhibitor. However, when the plasma clot was compacted
by centrifugation, the FXIIIa inhibitor had a strong inhi-
bitory effect, with 7.7-fold less tissue-type plasminogen
activator being required for 50% clot lysis in the presence
of the FXIIIa inhibitor. In both experiments, the effects
of the FXIIIa inhibitor were entirely dependent on the
cross-linking of a2-antiplasmin to fibrin. The FXIIIa
inhibitor reduced the amount of a2-antiplasmin present in
the compacted clots from approximately 30% to < 4%.
The results were confirmed with experiments in which
compaction was achieved by platelet-mediated clot retrac-
tion. Conclusions: Compaction or retraction of fibrin
clots reveals the strong antifibrinolytic effect of FXIII.
This is explained by the cross-linking of a2-antiplasmin to
fibrin by FXIIIa, which prevents the plasmin inhibitor
from being fully expelled from the clot during com-
paction/retraction.
Keywords: clot retraction; factor XIII; fibrinolysis;
hemostasis; thrombosis.
Introduction
Coagulation factor XIII strongly affects fibrin clot struc-
ture and function, and therefore plays a role in the patho-
physiology of arterial and venous thromboembolic
diseases [1]. FXIII is converted by thrombin into activated
FXIII (FXIIIa), which is a transglutaminase that forms
e-(c-glutamyl)lysyl cross-links between two polypeptide
chains [2]. The enzyme stabilizes fibrin by the formation
of primarily c-chain dimers and a-chain polymers. Cross-
linking makes fibrin clots insoluble in weak acid or urea
[3], and modifies their mechanical properties by increasing
the rigidity and elasticity [4,5]. This does not originate
from alterations in network morphology, but most likely
from stiffening of the individual fibers [6]. FXIII-mediated
cross-linking probably tightens the coupling between the
protofibrils within a fibrin fiber [7], which is associated
with slightly thinner fibers and a higher fiber density in a
clot [8].
Cross-linking might also affect the sensitivity of fibrin
clots to fibrinolysis, a process that prevents blood clots
from growing and occluding vessels by using the plas-
minogen–plasmin system [9]. However, this is a topic for
which there has been a longlasting debate about both the
magnitude of the effect of FXIIIa and the mechanisms
involved. When we take a look at the literature, it is use-
ful to distinguish studies that used purified fibrin clots
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and studies that used plasma or whole blood clots. In
purified systems, some authors found no effect of fibrin
cross-linking on clot lysis [5,10], whereas other authors
reported that the molecular cross-links producing a-chain
polymers, in particular the very high molecular weight
a-chain polymers obtained with elevated FXIIIa concen-
trations (possible provided by platelets), are associated
with the inhibition of fibrinolysis [11]. However, others
claimed that resistance to fibrinolysis was not induced by
a-chain polymer formation or c-chain dimer formation,
but by c-chain multimer formation, which only occurs
over a period of hours to days [12]. In studies showing
the inhibition of fibrinolysis by cross-linking, the effect is
often small [8].
When plasma or whole blood is used, FXIIIa produces
not only intramolecular cross-links within fibrin, but also
intermolecular cross-links between fibrin and a2-antiplas-
min (a2AP) [13]. This results in a significant inhibition of
physiologically occurring fibrinolysis [14]. The relative
contributions of fibrin–fibrin cross-links and fibrin–a2AP
cross-links to the inhibition of lysis of plasma or whole
blood clots by FXIIIa are not yet clear. Jansen et al. [15]
reported that fibrin–fibrin cross-linking does not con-
tribute significantly to the resistance of blood clots to fib-
rinolysis, but that cross-linking of a2AP to fibrin is
essential. This was recently confirmed by Fraser et al.
[16], who showed that the antifibrinolytic function of
FXIII in plasma clots is exclusively expressed through
a2AP cross-linking to fibrin. In contrast, Reed et al. [17]
reported that both fibrin–fibrin and a2AP–fibrin cross-
linking cause the resistance of experimental pulmonary
emboli to fibrinolysis.
Another source of the varying results between different
studies is the design of the clot lysis experiments [18].
However, it is still unclear why and how the expression of
the inhibition of clot lysis by FXIIIa varies so strongly in
different models and assays. Mutch et al. [19] showed
that model thrombi formed under flow in a Chandler
loop clearly reveal the effect of FXIII on fibrinolysis, but
the essential feature of this model for the effect is still
unknown. The present study deals with the mechanisms
of the inhibition of clot lysis by FXIII, and shows that
mechanical clot compaction, which is a model for physio-
logic clot retraction, is essential for fully revealing the
inhibition of plasma clot lysis.
Materials and methods
Materials
Purified a2AP was obtained from Calbiochem (San Diego,
CA, USA), human thrombin, bovine serum albumin (BSA)
and cytochalasin D (5 mg mL1 in dimethylsulfoxide
[DMSO]) were obtained from Sigma-Aldrich (St Louis,
MO, USA), tissue factor (Innovin) was obtained from
Dade Behring (Marburg, Germany), and recombinant
tissue-type plasminogen activator (t-PA; Actilyse) was
obtained from Boehringer Ingelheim (Ingelheim am Rein,
Germany). The active site-directed transglutaminase/
FXIIIa inhibitor 1,3-dimethyl-2-[(2-oxo-propyl)thio]imida-
zolium chloride (FXIIIa inhibitor) was obtained from
Zedira (Darmstadt, Germany) (catalog number D003). The
inhibitor was dissolved in 20% DMSO at a concentration
of 900 mM, further diluted with water to 40 mM, and stored
frozen in aliquots.
Human fibrinogen (depleted of plasminogen, von Wille-
brand factor, and fibronectin) was obtained from Enzyme
Research Laboratories (South Bend, IN, USA), and
labeled with fluorescein isothiocyanate (FITC) (Sigma-
Aldrich), as described elsewhere [20]. The molar fluores-
cein/fibrinogen ratio was 6.6.
Pooled normal plasma was prepared from citrated pla-
telet-poor plasma from 10 apparently healthy donors, and
was always used when plasma or normal plasma is speci-
fied in this article. Frozen a2AP-deficient plasma was
obtained from Affinity Biologicals (Ancaster, Ontario,
Canada). Platelet-rich plasma was prepared by centrifuga-
tion (265 9 g for 10 min) of citrated blood from three
apparently healthy donors, and each plasma was used
within 1.5 h after preparation. The platelet count ranged
from 346 9 109 L1 to 399 9 109 L1.
Turbidity assay of plasma clot lysis
The turbidity assay was performed essentially as described
previously [21]. However, clotting was induced by throm-
bin rather than by tissue factor and phospholipid vesicles.
In short, plasma was diluted 1.7-fold in assay buffer
(25 mM Hepes, 137 mM NaCl, 3.5 mM KCl, 1% [w/v] BSA,
pH 7.4) at room temperature. The diluted plasma (85 lL)
was added to the wells of a microtiter plate contain-
ing 15 lL of a reaction mixture, consisting of thrombin
(0.2, 1.0 or 3.3 NIH U mL1), CaCl2 (17 mM), t-PA
(30 ng mL1) and FXIIIa inhibitor (0 mM or 1 mM) in
assay buffer. The concentrations refer to the final concen-
trations in the 100-lL reaction volume. After mixing, each
well was covered with 50 lL of paraffin oil, and the micro-
titer plate was placed into the preheated chamber of a
microplate reader (Victor3; PerkinElmer, Waltham, MA,
USA), and the turbidity was measured as OD at 405 nm
every minute for 120 min at 37 °C. The clot lysis time
(CLT) was calculated as the time from the midpoint of
minimum turbidity to maximum turbidity, which repre-
sents clot formation, to the midpoint of maximum turbidity
to minimum turbidity, which represents clot lysis. When
the clot formation was too rapid, the clotting time was
roughly estimated. The assays were performed in triplicate.
Plasma clot lysis assay with and without clot compaction
Aliquots of 80 lL of plasma supplemented with FITC-
labeled fibrinogen (100 lg mL1) were mixed in Eppendorf
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tubes with 20 lL of a reaction mixture, consisting of tissue
factor (Innovin, diluted 1000-fold), CaCl2 (20 mM), t-PA
(0–100 ng mL1) and FXIIIa inhibitor (0 mM or 1 mM) in
turbidity assay buffer. The concentrations refer to the final
concentrations in the 100-lL reaction volume. After incu-
bation for 0.5 h at 37 °C, the clots were disconnected from
the tube wall, and compacted by centrifugation for 1 min
at 21 100 9 g. The incubation was then continued for
2.5 h at 37 °C with shaking. In the plasma clot lysis assay
without clot compaction, the clots were not centrifuged
after 0.5 h, but incubated for 3 h at 37 °C. After the incu-
bation, all clots were centrifuged for 1 min at 21 100 9 g.
Aliquots of 20 lL of the supernatants were mixed with
80 lL of Tris-buffered saline containing 0.01% Tween-20
(in triplicate), and the released fluorescence of FITC-
labeled fibrin degradation products was determined in the
microplate reader with 485 nm and 535 nm as the excita-
tion and the emission wavelengths, respectively, to calcu-
late the extent of lysis. The signal of fully lysed clots was
set at 100% lysis. This signal was 13% higher than the sig-
nal of the corresponding amount of FITC-labeled fibrino-
gen, indicating that internal quenching of the fluorescence
in FITC-labeled fibrinogen was decreased in FITC-labeled
fibrin degradation products.
The assays were additionally performed with a2AP-defi-
cient plasma instead of normal plasma. In these experi-
ments, the t-PA concentration range was 0–25 ng mL1
(final concentrations in the 100-lL reaction volume). In
control experiments, a2AP-deficient plasma was reconsti-
tuted with 45 lg mL1 purified a2AP.
Plasma clot lysis assay with and without platelet-mediated
clot retraction
Eppendorf tubes were treated with 1% Tween-20 in water
for 5 min to prevent fibrin sticking to the wall. Aliquots
of 80 lL of platelet-rich plasma supplemented with
FITC-labeled fibrinogen (100 lg mL1) were mixed in
these tubes with 20 lL of a reaction mixture, consisting
of tissue factor (Innovin, diluted 1000-fold), CaCl2
(20 mM), t-PA (0–100 ng mL1), cytochalasin D (0 lg
mL1 or 10 lg mL1) and FXIIIa inhibitor (0 mM or
1 mM) in turbidity assay buffer. The concentrations refer
to the final concentrations in the 100-lL reaction volume.
After incubation for 0.5 h at 37 °C, the incubation of the
retracted clots (those without cytochalasin D) was contin-
ued for 2.5 h at 37 °C with shaking. The incubation of
the non-retracted clots (those with cytochalasin D) was
continued for 2.5 h at 37 °C without shaking. The extent
of lysis was determined as described above for the com-
pacted and non-compacted clots.
Cross-linking of a2AP to fibrin
Clots were prepared essentially as in the plasma clot lysis
assay with clot compaction, but with a two-fold increase
in size. In more detail, aliquots of 160 lL of plasma were
mixed in Eppendorf tubes with 40 lL of a reaction mix-
ture, consisting of tissue factor (Innovin, diluted 1000-
fold), CaCl2 (20 mM) and FXIIIa inhibitor (0 mM or
1 mM) in turbidity assay buffer. The concentrations refer
to the final concentrations in the 200-lL reaction volume.
Controls did not contain tissue factor and CaCl2. After
incubation for 0.5 h at 37 °C, the clots were disconnected
from the tube wall, and compacted by centrifugation for
1 min at 21 100 9 g. The extents of compaction, as deter-
mined by weight analyses, amounted to 91.1% and
94.7%, respectively, for 0 mM and 1 mM FXIIIa inhibi-
tor. The distribution of a2AP after compaction was deter-
mined by measuring a2AP activity in the clot
supernatants, and by performing SDS-PAGE and western
blotting of the compacted clots. To this end, the clots
were washed five times with 500 lL of Tris-buffered sal-
ine containing 0.01% Tween-20 and 1 mM FXIIIa inhibi-
tor, and dissolved in 160 lL of SDS sample buffer
(Laemli) containing dithiothreitol for 15 min at 95 °C.
SDS-PAGE was performed on 7.5% Criterion Tris-HCl
gels (Biorad Laboratories, Hercules, CA, USA), and blots
were stained with goat anti-human a2AP IgG–horseradish
peroxidase (Affinity Biologicals) and BM blue POD sub-
strate (Sigma-Aldrich).
Miscellaneous
a2AP activity was determined with a chromogenic sub-
strate method (Berichrom a2AP kit; Siemens Healthcare,
Erlangen, Germany). Statistical analyses were performed
with SPSS for Windows, version 17.0 (SPSS, Chicago, IL,
USA), with the independent samples t-test. P-values of
< 0.05 were considered to be statistically significant.
Results
Effect of FXIII in a turbidity assay of plasma clot lysis
The effect of FXIII on plasma clot lysis was assessed by
using the transglutaminase/FXIIIa inhibitor 1,3-dimethyl-
2-[(2-oxo-propyl)thio]imidazolium chloride (FXIIIa inhi-
bitor). Citrated plasma was supplemented with t-PA, and
clotted with calcium and three different concentrations of
thrombin (0.2, 1.0 and 3.3 NIH U mL1) in the presence
or absence of 1 mM FXIIIa inhibitor. Each thrombin con-
centration yielded a somewhat different but reproducible
clot lysis profile (Fig. 1). FXIIIa inhibitor reduced the
CLT from 43.9  0.3 min to 37.8  1.1 min (mean 
standard deviation, n = 3, P = 0.001; 14% reduction)
at 0.2 NIH U mL1 thrombin, from 70.2  15.4 min
to 55.2  4.8 min (P = 0.18; 21% reduction) at 1.0 NIH
U mL1 thrombin, and from 75.3  5.6 min to 61.8 
1.8 min (P = 0.017, 18% reduction) at 3.3 NIH U mL1
thrombin. These results showed that FXIIIa inhibitor
slightly accelerated clot lysis under all conditions, implying
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that FXIII inhibited fibrinolysis to a small extent in this
assay.
Effect of FXIII on plasma clot lysis with and without clot
compaction
The effect of FXIII on plasma clot lysis was additionally
assessed in an assay that allowed experiments with and
without mechanical clot compaction. Without clot com-
paction, 50% clot lysis was obtained at 36.8  3.5
ng mL1 t-PA in the absence of FXIIIa inhibitor and at
23.6  5.8 ng mL1 t-PA, i.e. 1.6-fold less t-PA, in the
presence of FXIIIa inhibitor (Fig. 2A; Table 1;
P = 0.028). These results showed that FXIIIa inhibitor
slightly but significantly accelerated clot lysis, implying
that FXIII inhibited fibrinolysis only to a small extent in
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Fig. 1. Effect of activated factor XIII (FXIIIa) inhibitor on plasma
clot lysis in a turbidity assay. Three different thrombin concentra-
tions were used to clot plasma containing 30 ng mL1 tissue-type
plasminogen activator: (A) 0.2 NIH U mL1; (B) 1.0 NIH U mL1;
(C) 3.3 NIH U mL1). The clot lysis profiles were monitored by
measuring the OD at 405 nm during an incubation period of
120 min. Representative examples of the experiments are shown.
Solid lines: in the absence of FXIIIa inhibitor. Dotted lines: in the
presence of 1 mM FXIIIa inhibitor.
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Fig. 2. Effect of activated factor XIII (FXIIIa) inhibitor on plasma
clot lysis in a fluorometric assay. Plasma supplemented with fluores-
cein isothiocyanate-labeled fibrinogen was clotted in the presence of
varying concentrations of tissue-type plasminogen activator (t-PA),
and incubated for 3 h without (A) or with (B) mechanical com-
paction of the clot after 30 min. The experiments were carried out in
triplicate by performing them on three different days, and clot lysis
is shown as mean  standard error of the mean. Solid lines: in the
absence of FXIIIa inhibitor. Dotted lines: in the presence of 1 mM
FXIIIa inhibitor.
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this assay without compaction, similarly as in the turbid-
ity assay.
With clot compaction, 50% clot lysis was obtained at
80.0  22.6 ng mL1 t-PA in the absence of FXIIIa inhi-
bitor and at 10.4  1.9 ng mL1 t-PA, i.e. 7.7-fold less
t-PA, in the presence of FXIII inhibitor (Fig. 2B;
Table 1; P = 0.006). These results showed that FXIIIa
inhibitor strongly accelerated clot lysis, implying that
FXIII effectively inhibited fibrinolysis in this assay with
clot compaction, far more than in the assay without clot
compaction.
Role of a2AP
In order to determine to what extent the cross-linking of
a2AP to fibrin was responsible for the inhibition of
plasma clot lysis by FXIIIa, assays similar to those shown
in Fig. 2A,B were performed with a2AP-deficient plasma
rather than normal plasma.
Without clot compaction, 50% clot lysis was obtained
at 5.2  2.2 ng mL1 t-PA in the absence of FXIIIa
inhibitor and at 5.5  2.1 ng mL1 t-PA in the presence
of FXIIIa inhibitor (Fig. 3A; Table 1; P = 0.853). With
clot compaction, 50% clot lysis was obtained at
3.0  0.1 ng mL1 t-PA in the absence of FXIIIa inhibi-
tor and at 2.9  1.1 ng mL1 t-PA in the presence of
FXIII inhibitor (Fig. 3B; Table 1; P = 0.898). These
results showed that FXIIIa inhibitor had no significant
effects on clot lysis under these conditions, either with or
without clot compaction.
To prove that the absence of an effect of FXIIIa inhibi-
tor was really attributable to the deficiency of a2AP and
not to other variations in the plasma, a2AP-deficient
plasma was supplemented with 45 lg mL1 purified
a2AP, and plasma clot lysis was measured with clot com-
paction. In the presence of FXIIIa inhibitor, 50% clot
lysis was obtained at a 6.0-fold lower t-PA concentration
than in the absence of FXIIIa inhibitor (data not shown),
which is close to the factor of 7.7 obtained with normal
plasma (Table 1).
These results indicated that the inhibitory effects of
FXIII on fibrinolysis can be fully ascribed to cross-linking
of a2AP to fibrin, both in the assay with clot compaction
and in the assay without clot compaction.
Effect of FXIII on plasma clot lysis with and without
platelet-mediated clot retraction
The effect of FXIII on plasma clot lysis was also assessed
with platelet-rich plasma samples from three different
donors. Clot retraction occurred within 20 min. Control
clots that did not retract were prepared in the presence of
cytochalasin D. With these non-retracted clots, 50% clot
lysis was obtained at 72.0  14.7 ng mL–1 t-PA in the
absence of FXIIIa inhibitor and at 55.1  9.6 ng mL1
t-PA, i.e. 1.3-fold less t-PA, in the presence of FXIIIa
inhibitor (Fig. 4A; Table 1; P = 0.172). These results
showed that FXIIIa inhibitor slightly accelerated clot lysis
in each individual donor, although statistical significance
was not reached.
With clot retraction, 50% clot lysis was obtained at
59.3  12.1 ng mL1 t-PA in the absence of FXIIIa inhi-
bitor and at 14.3  4.1 ng mL1 t-PA, i.e. 4.2-fold less
t-PA, in the presence of FXIII inhibitor (Fig. 4B; Table 1;
P = 0.004). These results showed that FXIIIa inhibitor
strongly accelerated clot lysis, implying that FXIII effec-
tively inhibited fibrinolysis in this assay with clot retrac-
tion, far more than in the assay without clot retraction.
Distribution of a2AP after clot compaction
To obtain a better understanding of why compacted clots
fully revealed the antifibrinolytic and a2AP-dependent
effect of FXIII, the distribution of a2AP after clot
Table 1 Plasma clot composition and tissue-type plasminogen activator (t-PA) concentrations required for 50% clot lysis, derived from the
experiments shown in Figs 2–4
Plasma clot composition
Number of
experiments
t-PA concentration required for 50% lysis
Plasma
Clot compaction/
retraction
FXIIIa
inhibitor
Mean  SD
(ng mL1)
Ratio
( inh/+ inh)
P-value ( inh
versus + inh)
Normal   3 36.8  3.5 1.6 0.028*
Normal  + 3 23.6  5.8
Normal +  3 80.0  22.6 7.7 0.006*
Normal + + 3 10.4  1.9
a2AP-deficient   4 5.2  2.2 0.9 0.853
a2AP-deficient  + 4 5.5  2.1
a2AP-deficient +  4 3.0  0.1 1.0 0.898
a2AP-deficient + + 4 2.9  1.1
Platelet-rich   3 72.0  14.7 1.3 0.172
Platelet-rich  + 3 55.1  9.6
Platelet-rich +  3 59.3  12.1 4.2 0.004*
Platelet-rich + + 3 14.3  4.1
a2AP, a2-antiplasmin; FXIIIa, activated factor XIIIa; inh, FXIIIa inhibitor; SD, standard deviation. *Statistically significant difference.
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compaction was determined. As shown in Fig. 5A, the
supernatant of a compacted plasma clot contained 68.8%
a2AP of the unclotted control plasma, indicating that
31.2% remained in the clot. In contrast, in the presence
of FXIIIa inhibitor, the supernatant contained 96.1%,
indicating that only 3.9% remained in the clot, and that
nearly all a2AP was expelled from the clot during com-
paction. In other words, FXIII ensures that a significant
amount of a2AP remains in the clot during compaction.
This was confirmed in the experiment shown in Fig. 5B.
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Fig. 3. Effect of activated factor XIII (FXIIIa) inhibitor on plasma
clot lysis without a2-antiplasmin (a2AP) in a fluorometric assay.
a2AP-deficient plasma supplemented with fluorescein isothiocyanate-
labeled fibrinogen was clotted in the presence of varying concentra-
tions of tissue-type plasminogen activator (t-PA), and incubated for
3 h without (A) or with (B) mechanical compaction of the clot after
30 min. The experiments were carried out in quadruplicate by per-
forming them on four different days, and clot lysis is shown as
mean  standard error of the mean. Solid lines: in the absence of
FXIIIa inhibitor. Dotted lines: in the presence of 1 mM FXIIIa
inhibitor.
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Fig. 4. Effect of activated factor XIII (FXIIIa) inhibitor on platelet-
rich plasma clot lysis in a fluorometric assay. Platelet-rich plasma
supplemented with fluorescein isothiocyanate-labeled fibrinogen was
clotted in the presence of varying concentrations of tissue-type plas-
minogen activator (t-PA), and incubated for 3 h with (A) or without
(B) cytochalasin D, which prevents clot retraction. The experiments
were carried out in triplicate by performing them on three different
days with platelet-rich plasma from three different donors, and clot
lysis is shown as mean  standard error of the mean. Solid lines: in
the absence of FXIIIa inhibitor. Dotted lines: in the presence of
1 mM FXIIIa inhibitor.
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Lanes 1–4 showed that, in the absence of FXIIIa
inhibitor, the fibrin c-chain was fully converted into
c-dimer, and the fibrin a-chain partially into a-polymers
(> 150 kDa). Lanes 6–9 showed no a2AP in the clots
prepared in the presence of FXIIIa inhibitor, but signifi-
cant amounts of a2AP in complex with a-chain and
a-polymers in the clots prepared in the absence of FXIIIa
inhibitor. These experiments also showed that the concen-
tration of FXIIIa inhibitor (1 mM) was sufficiently high
to block FXIIIa, and that there was hardly any clot
binding or incorporation of a2AP in the absence of cross-
linking.
Discussion
This study further elucidates the mechanisms of the
antifibrinolytic effect of FXIII, and clarifies the literature
on this topic. Lysis of plasma clots without compaction,
as tested in the turbidity assay (Fig. 1) and in the assay
with FITC-labeled fibrin (Fig. 2A), was slightly but sig-
nificantly inhibited by FXIIIa. In the latter assay, a 1.6-
fold higher t-PA concentration was required for 50% lysis
in the presence of (endogenous) FXIIIa than in the
absence of FXIIIa (Table 1). As the inhibition of clot
lysis by FXIIIa was absent in clots from a2AP-deficient
plasma (Fig. 3A), the inhibition was caused by cross-link-
ing of a2AP to fibrin, and not by molecular cross-links
within fibrin. Our results imply that fibrin-bound a2AP is
a more efficient inhibitor of t-PA-induced fibrinolysis
than free a2AP in solution. The likely mechanism is that
fibrin-bound a2AP is localized on the fibrin surface, where
t-PA-induced plasminogen activation occurs and plasmin
has to perform its function. Our results are largely in
agreement with those of Sakata et al. [14], although this
study did not present data for non-compacted clots.
Other studies failed to show reproducible effects of FXIII
on lysis of non-compacted plasma clots [19], probably
because the effects are small.
a2AP circulates in two forms: a native form with a
methionine (Met) at the N-terminus, and a 12-residue
smaller form with an asparagine (Asn) at the N-terminus
[22–24]. Met-a2AP becomes cross-linked to fibrin approxi-
mately 13 times more slowly than Asn-a2AP, resulting in
a strongly (~ 50%) decreased CLT in a turbidity assay
[22]. However, the latter observation seems to be at odds
with the small effect of a total blockade of cross-linking
with the FXIIIa inhibitor in the turbidity assay of the pre-
sent study (14–21% decrease), and requires more research.
The most striking result of our study was that lysis of
compacted plasma clots was strongly inhibited by FXIIIa.
In the presence of (endogenous) FXIIIa, a 7.7-fold higher
t-PA concentration was required for 50% lysis than in
the absence of FXIIIa (Table 1). Again, as the inhibition
was not found in clots from a2AP-deficient plasma
(Fig. 3B), the inhibition was caused by cross-linking of
a2AP to fibrin, and not by molecular cross-links within
fibrin. Lysis of compacted clots was strongly inhibited by
FXIII, most likely because FXIIIa prevented a2AP from
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being expelled from the clot during compaction. In the
presence of FXIIIa, 31.2% of the a2AP remained associ-
ated with the clot, whereas in the absence of FXIIIa only
a negligible amount, i.e. 3.9%, of a2AP remained in the
clot (Fig. 5). The very low clot binding or incorporation
of a2AP in the absence of cross-linking does not confirm
the strong non-covalent interaction of a2AP with fibrin as
observed with surface plasmon resonance [25]. The pre-
sent study shows that two mechanisms are involved in the
inhibition of lysis of compacted plasma clots by FXIIIa:
(i) cross-linked a2AP is a more efficient inhibitor of plas-
min generated by t-PA on the fibrin surface than free
a2AP (small effect); and (ii) cross-linking of a2AP ensures
that a significant proportion of a2AP remains associated
with the clot during compaction (large effect).
These mechanisms are consistent with the observation
that a non-cross-linking derivative of a2AP produced sig-
nificantly less inhibition of lysis of compacted plasma
clots than native a2AP [14]. The critical role of com-
paction explains a long-standing controversy between
Gaffney and Whitaker [26], who found a strong inhibi-
tory effect of FXIII on lysis of plasma clots harvested by
being wound onto a glass rod (i.e. compaction), and
Rampling and Flexman [18], who found no inhibitory
effect when testing undisturbed plasma clots (i.e. no com-
paction). The role of compaction could also explain a
more recent observation that model thrombi formed
under flow in a Chandler loop reveal the inhibitory effect
of FXIII on fibrinolysis [19]. Our results indicate that it is
not the flow that represents the essential feature, but the
compaction of the clots that coincidentally takes place in
a Chandler loop. Flow in general is not necessarily associ-
ated with compaction, and should not be considered as
being essential for the expression of the antifibrinolytic
effect of FXIII.
The Chandler thrombus was presented as a model in
which the effects of cross-linking on fibrinolysis can be
determined quantitatively [19]. This model does indeed
seem to be convenient for resolving many remaining ques-
tions concerning the role of cross-linking in fibrinolysis.
However, for testing large numbers of samples, e.g. from
patient studies, the model would be less convenient. For
this purpose, mechanical compaction of clots by a simple
centrifugation step, as performed in this study, may be
more suitable.
As mentioned above, no inhibition of fibrinolysis by
FXIIIa could be demonstrated with clots prepared from
a2AP-deficient plasma, either with or without clot com-
paction. This suggests that the inhibition resulting from
the formation of fibrin–fibrin cross-links was too small for
detection in this system, and agrees with earlier reports
that fibrin–fibrin cross-linking does not contribute signifi-
cantly to the resistance of clots to fibrinolysis [15,16].
However, we cannot exclude the possibility that stronger
cross-linking resulting in very high molecular weight a-
chain polymers [11] and/or c-chain multimers [12] would
have resulted in resistance to fibrinolysis independently of
a2AP. The latter structures could also have been responsi-
ble for the observed resistance of experimental pulmonary
emboli to fibrinolysis by fibrin–fibrin cross-links [17].
This study shows that the inhibition of fibrinolysis by
FXIIIa is most pronounced in fibrin clots that are com-
pacted, because, in these clots, FXIIIa determines the
amount of a2AP that remains associated with the clot
(Fig. 6). In vivo clot compaction occurs by platelet-
mediated clot retraction. The clot lysis results of this
study were confirmed with experiments in which com-
paction was achieved by platelet-mediated clot retraction
rather than by centrifugation (Fig. 4), suggesting that this
study has in vivo relevance.
It is anticipated that the timing of a2AP cross-linking
and clot retraction may be important. In vitro experiments
have shown that a2AP cross-linking occurs within a few
minutes, whereas clot retraction requires dozens of min-
utes, suggesting that a2AP cross-linking is nearly complete
before clot retraction starts. However, in vivo data are lim-
ited, particularly in pathologic conditions. In theory, both
delayed a2AP cross-linking and accelerated retraction
could result in an a2AP-poor clot, possibly leading to fas-
ter clot lysis and a bleeding tendency. Not only the timing
but also the extent of a2AP cross-linking to fibrin could
regulate fibrinolysis. In vitro data from previous studies
[13,27] and from the present study (Fig. 5A) show that
only a proportion of a2AP is cross-linked to the fibrin
clot, suggesting that both increased and decreased cross-
linking could occur in vivo, potentially leading to a throm-
botic tendency and a bleeding tendency, respectively.
However, it is still not known how strongly the cross-link-
ing of a2AP varies among healthy individuals or patients.
Only a few preliminary reports have dealt with this topic
[28–31], and more clinical research is needed.
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